ARTICLE | Company News
Biogen, SurroMed deal
June 24, 2002 7:00 AM UTC
The companies will study multiple sclerosis (MS) patients to characterize their response to BGEN's Avonex interferon-beta-1a. SurroMed will identify biomarkers that are useful for developing MS drugs...